Press & News

ViewReleaseInStandardHtml

Boule Diagnostics wins another tender in India

Boule Diagnostics AB has won a public tender to blood banks in India for around 100 Medonic-systems in total. The systems will be delivered in first quarter 2017. The procuring authorities are Centre of Medicine Store and Distribution (CMSD) Lucknow, in the state of Uttar Pradesh. The Medonic-systems will be placed within blood bank units in different parts of Uttar Pradesh.

“The quality and versatility of our Medonic-systems helped us to win this tender. India is a large and fast growing market for Boule and we believe we can continue to grow and take market shares there. We are naturally delighted that our run of public tender successes is continuing as it confirms that demand for our high-quality products is increasing,” said Ernst Westman, Group President and CEO, Boule Diagnostics.

“An important advantage of the Medonic-system for the blood banks is the micro capillary function, a feature for fast blood sampling and screening of the donors, using a finger stick and a drop of blood, for the complete blood count analysis. This makes the system very effective to use, especially to blood banks with a high strain with many samples per day”, continues Ernst Westman.

For more information, please contact:
Ernst Westman, CEO and president, Boule Diagnostics AB, tel +46 708-60 88 63
 

About Boule Diagnostics AB

Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ Nordic since 2011. www.boule.se 

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:15 CET January 18 2016.